RTP Mobile Logo
Select Publications

Baker GM et al. Evaluation of breast and axillary lymph node specimens in breast cancer patients treated with neoadjuvant systemic therapy. Adv Anat Pathol 2019;26(4):221-34. Abstract

Cardoso F et al; MINDACT Investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375(8):717-29. Abstract

Denduluri N et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO Clinical Practice Guideline focused update. J Clin Oncol 2018;36(23):2433-43. Abstract

Filho OM et al. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. ASCO 2019;Abstract 502.

Francis PA et al; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379(2):122-37. Abstract

Geyer CE Jr et al. 21-gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer 2018;4:37. Abstract

Grossmith S et al. Multidisciplinary management of the axilla in patients with cT1-T2 N0 breast cancer undergoing primary mastectomy: Results from a prospective single-institution series. Ann Surg Oncol 2018;25(12):3527-34. Abstract

Kim HJ et al. Surgical treatment after neoadjuvant systemic therapy in young women with breast cancer: Results from a prospective cohort study. San Antonio Breast Cancer Symposium 2018;Abstract GS6-01.

Kim RS et al. Stromal tumor infiltrating lymphocytes in NRG Oncology/NSABP B-31 adjuvant trial for early-stage HER2-positive breast cancer. J Natl Cancer Inst 2019;[Epub ahead of print]. Abstract

Losk K et al. Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center. ASCO 2019;Abstract 549.

Losk K et al. Implementation of surgeon-initiated gene expression profile testing (Oncotype DX) among patients with early-stage breast cancer to reduce delays in chemotherapy initiation. J Oncol Pract 2017;13(9):e815-20. Abstract

Mamtani A, King TA. Lobular breast cancer: Different disease, different algorithms? Surg Oncol Clin N Am 2018;27(1):81-94. Abstract

Mittendorf EA, King TA. Routine use of Oncotype DX Recurrence Score testing in node-positive hormone receptor-positive HER2-negative breast cancer: The time has come. Ann Surg Oncol 2019;26(5):1173-5. Abstract

Moossdorff M et al. The potential impact of AMAROS on the management of the axilla in patients with clinical T1-2N0 breast cancer undergoing primary total mastectomy. Ann Surg Oncol 2018;25(9):2612-9. Abstract

Natsuhara KH et al. Impact of genomic assay testing and clinical factors on chemotherapy use after implementation of standardized testing criteria. Oncologist 2019;24(5):595-602. Abstract

Schneeweiss A et al. Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. ASCO 2019;Abstract 513.

Sparano JA et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019;380(25):2395-405. Abstract

Sparano JA et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379(2):111-21. Abstract

Valero MG et al. Surgeon variability and factors predicting for reoperation following breast-conserving surgery. Ann Surg Oncol 2018;25(9):2573-8. Abstract

Viale G et al; MINDACT Investigators. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Res Treat 2018;167(1):123-31. Abstract

von Minckwitz G et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380(7):617-28. Abstract

Weiss A et al. Incorporating biologic factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the supporting evidence. Surg Clin North Am 2018;98(4):687-702. Abstract